Bristol-Myers Discloses US Attorney Subpoena Over Abilify – NASDAQ

Last month, Bristol-Myers said its fourth-quarter earnings surged on lower tax provisions, while rising sales of anti-infective drugs and a new skin-cancer treatment helped lift revenue. Shares were up 2.2% at $32.75. The stock is up 6.9% over …